Investigating the Barrier Activity of Novel, Human Enhancer-Blocking Chromatin Insulators for Hematopoietic Stem Cell Gene Therapy
Despite the unequivocal success of hematopoietic stem and progenitor cell gene therapy, limitations still exist including genotoxicity and variegation/silencing of transgene expression. A class of DNA regulatory elements known as chromatin insulators (CIs) can mitigate both vector transcriptional silencing (barrier CIs) and vector-induced genotoxicity (enhancer-blocking CIs) and have been proposed as genetic modulators to minimize unwanted vector/genome interactions. Recently, a number of human, small-sized, and compact CIs bearing strong enhancer-blocking activity were identified. To ultimately uncover an ideal CI with a dual, enhancer-blocking and barrier activity, we interrogated these elements in vitro and in vivo. After initial screening of a series of these enhancer-blocking insulators for potential barrier activity, we identified three distinct categories with no, partial, or full protection against transgene silencing. Subsequently, the two CIs with full barrier activity (B4 and C1) were tested for their ability to protect against position effects in primary cells, after incorporation into lentiviral vectors (LVs) and transduction of human CD34+ cells. B4 and C1 did not adversely affect vector titers due to their small size, while they performed as strong barrier insulators in CD34+ cells, both in vitro and in vivo, shielding transgene's long-term expression, more robustly when placed in the forward orientation. Overall, the incorporation of these dual-functioning elements into therapeutic viral vectors will potentially provide a new generation of safer and more efficient LVs for all hematopoietic stem cell gene therapy applications.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Human gene therapy - 32(2021), 19-20 vom: 15. Okt., Seite 1186-1199 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Papayanni, Penelope-Georgia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Barrier activity |
|---|
| Anmerkungen: |
Date Completed 31.01.2022 Date Revised 03.10.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1089/hum.2021.142 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM330195018 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM330195018 | ||
| 003 | DE-627 | ||
| 005 | 20231225210749.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1089/hum.2021.142 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1100.xml |
| 035 | |a (DE-627)NLM330195018 | ||
| 035 | |a (NLM)34477013 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Papayanni, Penelope-Georgia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Investigating the Barrier Activity of Novel, Human Enhancer-Blocking Chromatin Insulators for Hematopoietic Stem Cell Gene Therapy |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.01.2022 | ||
| 500 | |a Date Revised 03.10.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Despite the unequivocal success of hematopoietic stem and progenitor cell gene therapy, limitations still exist including genotoxicity and variegation/silencing of transgene expression. A class of DNA regulatory elements known as chromatin insulators (CIs) can mitigate both vector transcriptional silencing (barrier CIs) and vector-induced genotoxicity (enhancer-blocking CIs) and have been proposed as genetic modulators to minimize unwanted vector/genome interactions. Recently, a number of human, small-sized, and compact CIs bearing strong enhancer-blocking activity were identified. To ultimately uncover an ideal CI with a dual, enhancer-blocking and barrier activity, we interrogated these elements in vitro and in vivo. After initial screening of a series of these enhancer-blocking insulators for potential barrier activity, we identified three distinct categories with no, partial, or full protection against transgene silencing. Subsequently, the two CIs with full barrier activity (B4 and C1) were tested for their ability to protect against position effects in primary cells, after incorporation into lentiviral vectors (LVs) and transduction of human CD34+ cells. B4 and C1 did not adversely affect vector titers due to their small size, while they performed as strong barrier insulators in CD34+ cells, both in vitro and in vivo, shielding transgene's long-term expression, more robustly when placed in the forward orientation. Overall, the incorporation of these dual-functioning elements into therapeutic viral vectors will potentially provide a new generation of safer and more efficient LVs for all hematopoietic stem cell gene therapy applications | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a CTCF-binding site | |
| 650 | 4 | |a barrier activity | |
| 650 | 4 | |a chromatin insulator | |
| 650 | 4 | |a gene therapy | |
| 650 | 4 | |a hematopoietic stem cells | |
| 650 | 7 | |a Chromatin |2 NLM | |
| 700 | 1 | |a Psatha, Nikoletta |e verfasserin |4 aut | |
| 700 | 1 | |a Christofi, Panayota |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Xing-Guo |e verfasserin |4 aut | |
| 700 | 1 | |a Melo, Pamela |e verfasserin |4 aut | |
| 700 | 1 | |a Volpin, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Montini, Eugenio |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Mingdong |e verfasserin |4 aut | |
| 700 | 1 | |a Kaltsounis, Georgios |e verfasserin |4 aut | |
| 700 | 1 | |a Yiangou, Minas |e verfasserin |4 aut | |
| 700 | 1 | |a Emery, David W |e verfasserin |4 aut | |
| 700 | 1 | |a Anagnostopoulos, Achilles |e verfasserin |4 aut | |
| 700 | 1 | |a Papayannopoulou, Thalia |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Suming |e verfasserin |4 aut | |
| 700 | 1 | |a Stamatoyannopoulos, George |e verfasserin |4 aut | |
| 700 | 1 | |a Yannaki, Evangelia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Human gene therapy |d 1990 |g 32(2021), 19-20 vom: 15. Okt., Seite 1186-1199 |w (DE-627)NLM012951587 |x 1557-7422 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2021 |g number:19-20 |g day:15 |g month:10 |g pages:1186-1199 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1089/hum.2021.142 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2021 |e 19-20 |b 15 |c 10 |h 1186-1199 | ||